A citation-based method for searching scientific literature

Andrea Sartore-Bianchi, Elio Gregory Pizzutilo, Giovanna Marrapese, Federica Tosi, Giulio Cerea, Salvatore Siena. Expert Rev Anticancer Ther 2020
Times Cited: 9







List of co-cited articles
95 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
44

Olmutinib: First Global Approval.
Esther S Kim. Drugs 2016
79
33

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Yi-Long Wu, Ying Cheng, Xiangdong Zhou, Ki Hyeong Lee, Kazuhiko Nakagawa, Seiji Niho, Fumito Tsuji, Rolf Linke, Rafael Rosell, Jesus Corral,[...]. Lancet Oncol 2017
468
33

Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer.
Alessio Amatu, Alessio Somaschini, Giulio Cerea, Roberta Bosotti, Emanuele Valtorta, Pasquale Buonandi, Giovanna Marrapese, Silvio Veronese, David Luo, Zachary Hornby,[...]. Br J Cancer 2015
46
22

Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
Alexander Drilon, Geoffrey R Oxnard, Daniel S W Tan, Herbert H F Loong, Melissa Johnson, Justin Gainor, Caroline E McCoach, Oliver Gautschi, Benjamin Besse, Byoung C Cho,[...]. N Engl J Med 2020
128
22

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
Manabu Soda, Young Lim Choi, Munehiro Enomoto, Shuji Takada, Yoshihiro Yamashita, Shunpei Ishikawa, Shin-ichiro Fujiwara, Hideki Watanabe, Kentaro Kurashina, Hisashi Hatanaka,[...]. Nature 2007
22

PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical Models.
Helen Y Zou, Luc Friboulet, David P Kodack, Lars D Engstrom, Qiuhua Li, Melissa West, Ruth W Tang, Hui Wang, Konstantinos Tsaparikos, Jinwei Wang,[...]. Cancer Cell 2015
256
22

Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.
Mi Ran Yun, Dong Hwi Kim, Seok-Young Kim, Hyeong-Seok Joo, You Won Lee, Hun Mi Choi, Chae Won Park, Seong Gu Heo, Han Na Kang, Sung Sook Lee,[...]. Clin Cancer Res 2020
18
22

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Alexander Drilon, Salvatore Siena, Rafal Dziadziuszko, Fabrice Barlesi, Matthew G Krebs, Alice T Shaw, Filippo de Braud, Christian Rolfo, Myung-Ju Ahn, Jürgen Wolf,[...]. Lancet Oncol 2020
112
22

Molecular characterization of cancers with NTRK gene fusions.
Zoran Gatalica, Joanne Xiu, Jeffrey Swensen, Semir Vranic. Mod Pathol 2019
185
22

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
David S Hong, Steven G DuBois, Shivaani Kummar, Anna F Farago, Catherine M Albert, Kristoffer S Rohrberg, Cornelis M van Tilburg, Ramamoorthy Nagasubramanian, Jordan D Berlin, Noah Federman,[...]. Lancet Oncol 2020
184
22

Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors.
Dazhi Liu, Michael Offin, Stephen Harnicar, Bob T Li, Alexander Drilon. Ther Clin Risk Manag 2018
45
22

NTRK fusion-positive cancers and TRK inhibitor therapy.
Emiliano Cocco, Maurizio Scaltriti, Alexander Drilon. Nat Rev Clin Oncol 2018
426
22



Brigatinib: Novel ALK Inhibitor for Non-Small-Cell Lung Cancer.
Sara A Spencer, Angela C Riley, Adia Matthew, Anthony J Di Pasqua. Ann Pharmacother 2019
9
22



Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer.
Mariacarmela Santarpia, Giuseppe Altavilla, Rafael Rosell. Expert Rev Respir Med 2015
22
22

Neratinib: First Global Approval.
Emma D Deeks. Drugs 2017
37
22

Targeting oncogenic ALK: a promising strategy for cancer treatment.
Enrique Grande, María-Victoria Bolós, Edurne Arriola. Mol Cancer Ther 2011
70
22

Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms.
Kerstin Maria Kampa-Schittenhelm, Michael Charles Heinrich, Figen Akmut, Hartmut Döhner, Konstanze Döhner, Marcus Matthias Schittenhelm. Mol Cancer 2013
73
22


Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
Naveen Pemmaraju, Hagop Kantarjian, Michael Andreeff, Jorge Cortes, Farhad Ravandi. Expert Opin Investig Drugs 2014
25
22

Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer With or Without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis.
Koichi Ando, Kaho Akimoto, Hiroki Sato, Ryo Manabe, Yasunari Kishino, Tetsuya Homma, Sojiro Kusumoto, Toshimitsu Yamaoka, Akihiko Tanaka, Tohru Ohmori,[...]. Cancers (Basel) 2020
13
22

Tivozanib: status of development.
Muhammad Omer Jamil, Amanda Hathaway, Amitkumar Mehta. Curr Oncol Rep 2015
22
22

Pyrotinib: First Global Approval.
Hannah A Blair. Drugs 2018
45
22

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.
Bryan D Smith, Michael D Kaufman, Wei-Ping Lu, Anu Gupta, Cynthia B Leary, Scott C Wise, Thomas J Rutkoski, Yu Mi Ahn, Gada Al-Ani, Stacie L Bulfer,[...]. Cancer Cell 2019
71
22

Midostaurin: its odyssey from discovery to approval for treating acute myeloid leukemia and advanced systemic mastocytosis.
Richard M Stone, Paul W Manley, Richard A Larson, Renaud Capdeville. Blood Adv 2018
75
22

Zanubrutinib: First Approval.
Yahiya Y Syed. Drugs 2020
37
22

Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond.
Daniela Di Lisi, Rosalinda Madonna, Concetta Zito, Enrico Bronte, Giuseppe Badalamenti, Paolo Parrella, Ines Monte, Carlo Gabriele Tocchetti, Antonio Russo, Giuseppina Novo. Int J Cardiol 2017
32
22

Lenvatinib: A Review in Refractory Thyroid Cancer.
James E Frampton. Target Oncol 2016
20
22


Role of Bruton's tyrosine kinase in B cells and malignancies.
Simar Pal Singh, Floris Dammeijer, Rudi W Hendriks. Mol Cancer 2018
180
22

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms.
Toshimitsu Yamaoka, Motoi Ohba, Tohru Ohmori. Int J Mol Sci 2017
58
22

Entrectinib: First Global Approval.
Zaina T Al-Salama, Susan J Keam. Drugs 2019
38
22


Anaplastic lymphoma kinase inhibitors: an updated patent review (2014-2018).
Yi-Min Liu, Chun-Nan Kuo, Jing-Ping Liou. Expert Opin Ther Pat 2020
3
66


Pexidartinib: First Approval.
Yvette N Lamb. Drugs 2019
39
22

Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review.
Eugen F Mesaros, Gregory R Ott, Bruce D Dorsey. Expert Opin Ther Pat 2014
16
22

Gilteritinib: First Global Approval.
Sohita Dhillon. Drugs 2019
43
22

Avapritinib: First Approval.
Sohita Dhillon. Drugs 2020
25
22

Antitumor activity of alectinib, a selective ALK inhibitor, in an ALK-positive NSCLC cell line harboring G1269A mutation: Efficacy of alectinib against ALK G1269A mutated cells.
Yasushi Yoshimura, Mitsue Kurasawa, Keigo Yorozu, Oscar Puig, Walter Bordogna, Naoki Harada. Cancer Chemother Pharmacol 2016
15
22

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer.
Cynthia X Ma, Ron Bose, Feng Gao, Rachel A Freedman, Melinda L Telli, Gretchen Kimmick, Eric Winer, Michael Naughton, Matthew P Goetz, Christy Russell,[...]. Clin Cancer Res 2017
96
22

Inhibitors of anaplastic lymphoma kinase: a patent review.
Karen L Milkiewicz, Gregory R Ott. Expert Opin Ther Pat 2010
19
22

Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity.
Hwei-Ru Tsou, Elsebe G Overbeek-Klumpers, William A Hallett, Marvin F Reich, M Brawner Floyd, Bernard D Johnson, Ronald S Michalak, Ramaswamy Nilakantan, Carolyn Discafani, Jonathan Golas,[...]. J Med Chem 2005
206
22



Catalytic mechanisms and regulation of protein kinases.
Zhihong Wang, Philip A Cole. Methods Enzymol 2014
54
22


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.